Loading…
DILACORT is a brand name for Prednisolone. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Allergy and anaphylaxis: bronchial asthma, drug hypersensitivity reactions, serum sickness, angioneurotic oedema, anaphylaxis. Arteritis/collagenosis: giant cell arteritis/polymyalgia rheumatica, mixed connective tissue disease, polyarteritis nodosa, polymyositis. Blood disorders: haemolytic anaemia (auto-immune),…
Verbatim from this product's MHRA label. Tap a section to expand.
Posology The initial dosage of Dilacort Gastro-Resistant Tablets may vary from 5mg to 60mg daily depending on the disorder being treated. Divided daily dosage is usually used. The following therapeutic guidelines should be kept in mind for all therapy with corticosteroids: Corticosteroids are palliative symptomatic treatment by virtue of their anti- inflammatory effects; they are never curative.
The appropriate individual dose must be determined by trial and error and must be re-evaluated regularly according to activity of the disease. As corticosteroid therapy becomes prolonged and as the dose is increased, the incidence of disabling side-effects increases.
In general, initial dosage shall be maintained or adjusted until the anticipated response is observed. The dose should be gradually reduced until the lowest dose which will maintain an adequate clinical response is reached. 4). 5mg prednisolone or equivalent) for greater than 3 weeks, withdrawal should not be abrupt.
How dose reduction should be carried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced. Clinical assessment of disease activity may be needed during withdrawal. If the disease is unlikely to relapse on withdrawal of systemic corticosteroids but there is uncertainty about hypothalamic-pituitary-adrenal (HPA) suppression, the dose of corticosteroid may be reduced rapidly to physiological doses.
5mg of prednisolone is reached, dose reduction should be slower to allow the HPA-axis to recover. Abrupt withdrawal of systemic corticosteroid treatment, which has continued up to 3 weeks is appropriate if it is considered that the disease is unlikely to relapse.
Abrupt withdrawal of doses of up to 40mg daily of prednisolone, or equivalent for 3 weeks is unlikely to lead to clinically relevant HPA-axis suppression, in the majority of patients. In the following patient groups, gradual withdrawal of systemic corticosteroid therapy should be considered even after courses lasting 3 weeks or less: • patients who have had repeated courses of systemic corticosteroids, particularly if taken for greater than 3 weeks.
• when a short course has been prescribed within one year of cessation of long-term therapy (months or years). • patients who may have reasons for adrenocortical insufficiency other than exogenous corticosteroid therapy. • patients receiving doses of systemic corticosteroid greater than 40mg daily of prednisolone (or equivalent).
A wide range of psychiatric reactions including affective disorders (such as irritable, euphoric, depressed and labile mood, and suicidal thoughts), psychotic reactions (including mania, delusions, hallucinations, and aggravation of schizophrenia), behavioural disturbances, irritability, anxiety, sleep disturbances, and cognitive dysfunction including confusion and amnesia have been reported.
Reactions are common and may occur in both adults and children. In adults, the frequency of severe reactions has been estimated to be 5-6%. Psychological effects have been reported on withdrawal of corticosteroids; the frequency is unknown.
4). Undesirable effects are listed by MedDRA System Organ Classes.
Assessment of undesirable effects is based on the following frequency groupings:
Very common: ≥1/10 Common: ≥1/100 to <1/10 Uncommon: ≥1/1,000 to <1/100 Rare: ≥1/10,000 to <1/1,000 Very rare: <1/10,000 Not known: cannot be estimated from the available data System Organ Class Frequency Undesirable Effect Infections and infestations Not known Increases susceptibility to, and severity of infections1, opportunistic infections, recurrence of dormant tuberculosis2, oesophageal candidiasis.
Blood and lymphatic system disorders Not known Leucocytosis. Immune system disorders Not known Hypersensitivity including anaphylaxis. Scleroderma renal crisis3. Endocrine disorders Not known Suppression of the hypothalamo- pituitary adrenal axis4, cushingoid facies, impaired carbohydrate tolerance with increased requirement for antidiabetic therapy, manifestation of latent diabetes mellitus.
Not known Sodium and water retention, hypokalaemic alkalosis, potassium loss, negative nitrogen and calcium balance, glucose intolerance and protein catabolism. Increase both high and low density lipoprotein cholesterol concentration in the blood.
8). Symptoms typically emerge within a few days or weeks of starting the treatment. 5), although dose levels do not allow prediction of the onset, type, severity or duration of reactions. Most reactions recover after either dose reduction or withdrawal, although specific treatment may be necessary.
Patients/carers should be encouraged to seek medical advice if worrying psychological symptoms develop, especially if depressed mood or suicidal ideation is suspected. Patients/carers should also be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids, although such reactions have been reported infrequently.
Particular care is required when considering the use of systemic corticosteroids in patients with existing or previous history of severe affective disorders in themselves or in their first degree relatives. These would include depressive or manic-depressive illness and previous steroid psychosis.
5). 8). Although calciphylaxis is most commonly observed in patients who have end stage kidney failure, it has also been reported in patients taking corticosteroids who have minimal or no renal impairment and normal calcium, phosphate and parathyroid hormone levels.
Patients/carers should be advised to seek medical advice if symptoms develop. Caution is necessary when oral corticosteroids, including prednisolone, are prescribed in patients with the following conditions, and frequent patient monitoring is necessary.
• Tuberculosis: Those with a previous history of, or X-ray changes characteristic of, tuberculosis. The emergence of active tuberculosis can, however, be prevented by the prophylactic use of anti-tuberculosis therapy. • Inflammatory bowel disease: Symptoms recurred in a patient with Crohn’s disease on changing from conventional to enteric-coated tablets of prednisolone.
1. • Systemic infections unless specific anti-infective therapy is employed. • Ocular herpes simplex because of possible perforation.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Prednisolone in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
• patients repeatedly taking doses in the evening. 4) If there is lack of a satisfactory clinical response to Dilacort Gastro-Resistant Tablets, the drug should be gradually discontinued and the patient transferred to alternative therapy.
Intermittent dosage regimen:
A single dose of Dilacort Gastro-Resistant Tablets in the morning on alternate days or at longer intervals is acceptable therapy for some patients. When this regimen is practical, the degree of pituitary-adrenal suppression can be minimised.
Specific dosage guidelines:
The following recommendations for some corticosteroid-responsive disorders are for guidance only. Acute or severe disease may require initial high dose therapy with reduction to the lowest effective maintenance dose as soon as possible.
5mg daily during chronic treatment.
Allergic and skin disorders:
Initial doses of 5-15mg daily are commonly adequate.
Collagenosis:
Initial doses of 20-30mg daily are frequently effective. Those with more severe symptoms may require higher doses.
Rheumatoid arthritis:
The usual initial dose is 10-15mg daily. The lowest daily maintenance dose compatible with tolerable symptomatic relief is recommended.
Blood disorders and lymphoma:
An initial daily dose of 15-60mg is often necessary with reduction after an adequate clinical or haematological response. Higher doses may be necessary to induce remission in acute leukaemia. 4). 8). Alternate day dosage is preferable where possible.
Method of administration Dilacort Gastro-Resistant Tablets are for oral use only.
Increased appetite5. Weight gain, obesity, hyperglycaemia, dyslipidaemia. Metabolism and nutrition disorders Very rare Calciphylaxis6. Psychiatric disorders Common Irritability, depressed and labile mood, suicidal thoughts, psychotic reactions, mania, delusions, hallucinations, and aggravation of schizophrenia, behavioural disturbances, irritability, anxiety, sleep disturbances, and cognitive dysfunction including confusion and amnesia.
System Organ Class Frequency Undesirable Effect Not known Euphoria, psychological dependence, depression. Nervous system disorders Not known Depression, insomnia, dizziness, headache, vertigo. Raised intracranial pressure with papilloedema (pseudotumor cerebri)7.
Aggravation of epilepsy, epidural lipomatosis, vertebrobasilar stroke8. Eye disorders Not known Glaucoma, papilloedema, posterior subcapsular cataracts, nuclear cataracts (particularly in children), exophthalmos, corneal or scleral thinning, exacerbation of ophthalmic viral or fungal disease.
Severe exacerbation of bullous exudative retinal detachment; lasting visual loss in some patients with idiopathic central serous chorioretinopathy9. Ear and labyrinth disorders Not known Vertigo. Cardiac disorders Not known Congestive heart failure in susceptible patients, hypertension, increased risk of heart failure.
Increased risk of cardiovascular disease, including myocardial infarction10. Bradycardia*. Vascular disorders Not known Thromboembolism. Gastrointestinal disorders Not known Dyspepsia, nausea, peptic ulceration with perforation and haemorrhage, abdominal distension, abdominal pain, diarrhoea, oesophageal ulceration, acute pancreatitis.
Skin and subcutaneous tissue disorders Not known Hirsutism, skin atrophy, bruising, striae, telangiectasia, acne, increased sweating, pruritis, rash, urticaria. Musculoskeletal and connective tissue disorders Not known Proximal myopathy, osteoporosis, vertebral and long bone fractures, avascular osteonecrosis, tendon rupture, tendinopathies (particularly of the Achilles and patellar tendons), myalgia, growth suppression in infancy, childhood and adolescence.
Reproductive system and breast disorders Not known Menstrual irregularity, amenorrhoea. General disorders and administration site conditions Not known Fatigue, malaise, impaired healing. Investigations Not known Increased intra-ocular pressure, may suppress reactions to skin tests.
1. With suppression of clinical symptoms and signs. 2. 4 Special warnings and precautions for use. 3. Amongst the different subpopulations the occurrence of scleroderma renal crisis varies. The highest risk has been reported in patients with diffuse systemic sclerosis.
The lowest risk has been reported in patients with limited systemic sclerosis (2%) and juvenile onset systemic sclerosis (1%) 4. Particularly in times of stress, as in trauma, surgery or illness.
This was not an isolated occurrence in the author’s unit, and it was advocated that only non-enteric coated prednisolone tablets should be used in Crohn’s disease, and that the enteric coated form should be used with caution in any condition characterised by diarrhoea or a rapid transit time.
• Hypertension. • Congestive heart failure. • Liver failure. • Hepatic disease: In patients with acute and active hepatitis, protein binding of the glucocorticoids will be reduced and peak concentrations of administered glucocorticoids increased.
Elimination of prednisolone will also be impaired. There is an enhanced effect of corticosteroids in patients with cirrhosis. • Renal insufficiency. • Diabetes mellitus or in those with a family history of diabetes. • Osteoporosis: This is of special importance in post-menopausal females who are at particular risk.
• Corticosteroid requirements may be reduced in menopausal and post- menopausal women. • Patients with a history of severe affective disorders and particularly those with a previous history of steroid-induced psychoses. • Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids including prednisolone.
• Epilepsy, and/or seizure disorders • Peptic ulceration. • Previous steroid myopathy. • Glucocorticoids should be used cautiously in patients with myasthenia gravis receiving anticholinesterase therapy. • Because cortisone has been reported rarely to increase blood coagulability and to precipitate intravascular thrombosis, thromboembolism, and thrombophlebitis, corticosteroids should be used with caution in patients with thromboembolic disorders.
• Duchenne’s muscular dystrophy: transient rhabdomyolysis and myoglobinuria may occur following strenuous physical activity. It is not known whether this is due to prednisolone itself or the increased physical activity. Undesirable effects may be minimised by using the lowest effective dose for the minimum period and by administering the daily requirement as a single morning dose on alternate days.
2). Adrenocortical Insufficiency Pharmacologic doses of corticosteroids administered for prolonged periods may result in hypothalamic-pituitary-adrenal (HPA) suppression (secondary adrenocortical insufficiency). The degree and duration of adrenocortical insufficiency produced is variable among patients and depends on the dose, frequency, time of administration, and duration of glucocorticoid therapy.
In addition, acute adrenal insufficiency leading to a fatal outcome may occur if glucocorticoids are withdrawn abruptly. Drug-induced secondary adrenocortical insufficiency may therefore be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.
Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. During prolonged therapy any intercurrent illness, trauma, or surgical procedure will require a temporary increase in dosage; if corticosteroids have been stopped following prolonged therapy they may need to be temporarily re-introduced.
Patients should carry “Steroid treatment” cards which give clear guidance on the precautions to be taken to minimise risk and which provide details of prescriber, drug, dosage and […]